Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms

Expert Review of Vaccines

Volumn 13, Issue 7, 2014, Pages 873-883

  Luke, Catherine J ^a   Subbarao, Kanta ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

influenza vaccine; pandemic influenza vaccine; prime boost

Indexed keywords

DNA VACCINE; INACTIVATED VACCINE; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; LIVE VACCINE; RECOMBINANT VACCINE; IMMUNOLOGICAL ADJUVANT; SUBUNIT VACCINE; VIRUS ANTIGEN;

2009 H1N1 INFLUENZA; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGENICITY; AVIAN INFLUENZA; BIOSAFETY; CELLULAR IMMUNITY; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); GENETIC REASSORTMENT; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H2N2; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N9; MEMORY CELL; NONHUMAN; PANDEMIC INFLUENZA; PATHOGENICITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA; SWINE INFLUENZA VIRUS; VACCINATION; VACCINE PRODUCTION; ANTIBODY PRODUCTION; DISEASE OUTBREAKS; DRUG DESIGN; IMMUNIZATION; IMMUNOLOGY; INFLUENZA, HUMAN; PANDEMICS;

ADJUVANTS, IMMUNOLOGIC; ANTIBODY FORMATION; ANTIGENS, VIRAL; DISEASE OUTBREAKS; DRUG DESIGN; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, INACTIVATED; VACCINES, SUBUNIT;

EID: 84902346773     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.922416     Document Type: Review

References (64)

1. World Health Organization. Avian influenza: assessing the pandemic threat. 2005. Available from: www.who.int/influenza/resources/documents/h5n1- assessing-pandemic-threat/en/
2. World Health Organization. Influenza (Seasonal) Fact Sheet. 2009. Available from: www.who.int/mediacentre/factsheets/fs211/en/
3. Palese P, Shaw ML. Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, Griffin DE, et al. editors. Fields virology. Lippincott, Williams and Wilkins; Philadelphia, PA, USA: 2007. p. 1647-989
4. Jagger BW, Wise HM, Kash JC, et al. An overlapping protein-coding region in influenza A virus segment 3 modulated the host response. Science 2012;337:199-204
5. Tong S, Li Y, Rivailler P, et al. A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci USA 2012;109(11):4269-74
6. Tong S, Zhu X, Li Y, et al. New world bats harbor diverse influenza A viruses. PLoS Pathog 2013;9(10):e1003657
7. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med 2002;76(1):105-15
8. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009;361(20):1945-52
9. O'Donnell CD, Wright A, Vogel LN, et al. Effect of priming with H1N1 influenza viruses of variable antigenic distances on challenge with 2009 pandemic H1N1 virus. J Virol 2012;86(16):8625-33
10. Dawood FS, Iuliano AD, Reed C, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012; 12(9):687-95
11. Simonsen L, Spreeuwenberg P, Lustig R, et al. Global mortality estimates for the 2009 influenza pandemic from the GLaMOR project: a modeling study. PLoS Med 2013;10(11):e1001558
12. Belser JA, Bridges CB, Katz JM, Tumpey TM. Past, present, and possible future human infection with influenza virus A subtype H7. Emerg Infect Dis 2009; 15(6):859-65
13. Neumann G, Chen H, Gao GF, et al. H5N1 influenza viruses: outbreaks and biological properties. Cell Res 2010;20(1): 51-61
14. Peiris JS. Avian influenza viruses in humans. Rev Sci Tech Off Int Epiz 2009;28:161-74
15. Reperant LA, Kuiken T, Osterhaus AD. Influenza viruses: from birds to humans. Hum Vaccin Immunother 2012;8(1):7-16
16. Subbarao K, Katz J. Avian influenza viruses infecting humans. Cell Mol Life Sci 2000; 57(12):1770-84
17. World Health Organization. 2014. Available from: www.who.int/influenza/ human-animal-interface-/EN-GIP-20140124 CumulativeNumberH5N1cases.pdf?ua=1
18. World Health Organization. 2014. Available from: www.who.int/influenza/ human-animal-interface/influenza/influenza-h7n9/Risk-Assessment/en
19. Fiore AE, Bridges CB, Katz JM, Cox NJ. Inactivated influenza vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. Elsevier Saunders; Philadelphia, PA, USA: 2013. p. 257-93.
20. Luke CJ, Lakdawala SS, Subbarao K. Influenza vaccine-live. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. Elsevier Saunders; Philadelphia, PA, USA: 2013. p. 294-311.
21. Basha S, Hazenfeld S, Brady RC, Subbramanian RA. Comparison of antibody and T-cell responses elicited by licensed inactivated-and live-attenuated influenza vaccines against H3N2 hemagglutinin. Hum Immunol 2011;72(6):463-9
22. Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986;24:157-60 (Pubitemid 16090261)
23. Clements ML, Murphy BR. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 1986;23:66-72 (Pubitemid 16186972)
24. Forrest DB, Pride MW, Dunning AJ, et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008;15:1042-53 (Pubitemid 352018317)
25. He XS, Holmes TH, Zhang C, et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006;80:11756-66 (Pubitemid 44788888)
26. Hoft DF, Babusis E, Worku S, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 2011;204(6): 845-53
27. Lanthier PA, Huston GE, Moquin A, et al. Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses. Vaccine 2011;29(44): 7849-56
28. Sasaki S, He XS, Holmes TH, et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One 2008;3:e2975
29. Sasaki S, Jaimes MC, Holmes TH, et al. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007;81:215-28 (Pubitemid 44975162)
30. Subbarao K, Matsuoka Y. The prospects and challenges of universal vaccines for influenza. Trends Microbiol 2013;21(7): 350-8
31. Baz M, Luke CJ, Cheng X, et al. H5N1 vaccines in humans. Virus Res 2013; 178(1):78-98.
32. Couch RB, Patel SM, Wade-Bowers CL, Nino D. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS One 2012;7(12):e49704
33. Cox RJ, Madhun AS, Hauge S, et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 2009;27(13):1889-97
34. Hehme N, Engelmann H, Kunzel W, et al. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol 2002;191:203-8 (Pubitemid 35435768)
35. World Health Organization. 2007. Available from: www.who.int/ immunization/diseases/influenza/clinical-evaluation-tables/en/
36. Luke CJ, Subbarao K. Vaccines for pandemic influenza. Emerg Infect Dis 2006;12:66-72 (Pubitemid 43143538)
37. Subbarao K, Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 2007;7(4):267-78 (Pubitemid 46480953)
38. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001;357(9272):1937-43. (Pubitemid 32568336)
39. Subbarao K, Chen H, Swayne D, et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 2003;305(1): 192-200 (Pubitemid 36062823)
40. Webby RJ, Perez DR, Coleman JS, et al. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 2004;363(9415): 1099-103 (Pubitemid 38452781)
41. Ehrlich HJ, Muller M, Oh HM, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008;358(24):2573-84 (Pubitemid 351831358)
42. Howard MK, Kistner O, Barrett PN. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol Chem 2008;389(5):569-77 (Pubitemid 351874194)
43. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza AV. Abdel-Ghafar AN, Chotpitayasunondh T, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008;358(3): 261-73
44. World Health Organization. 2014. Available from: www.who.int/influenza/ vaccines/virus/201402-h5h7h9h10-vaccinevirusupdate.pdf?
45. Manner in adults. J Infect Dis 2013;208(3): 413-17.
46. Murphy BR, Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 2002;15: 295-323 (Pubitemid 34651533)
47. Karron RA, Talaat K, Luke C, et al. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 2009;27(36): 4953-60.
48. Talaat KR, Luke CJ, Khurana S, et al. A live attenuated H5N1 vaccine induces long-term immunity in the absence of a primary antibody response. J Infect Dis 2014. [Epub ahead of print].
49. Bentebibel SE, Lopez S, Obermoser G, et al. Induction of ICOS+CXCR3+CXCR5 + TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med 2013;5(176):176ra132.
50. Gurwith M, Lock M, Taylor EM, et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 2013; 13(3):238-50.
51. Bright RA, Carter DM, Crevar CJ, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008;3(1):e1501
52. Khurana S, Wu J, Verma N, et al. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol 2011;85(21):10945-54
53. Landry N, Ward BJ, Trepanier S, et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 2010; 5(12):e15559
54. Antrobus RD, Berthoud TK, Mullarkey CE, et al. Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. Mol Ther 2014;22(1):233-8
55. Antrobus RD, Coughlan L, Berthoud TK, et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens. Mol Ther 2014;22(3): 668-74
56. Lillie PJ, Berthoud TK, Powell TJ, et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP +M1, in humans. Clin Infect Dis 2012; 55(1):19-25
57. Powell TJ, Peng Y, Berthoud TK, et al. Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP +M1 vaccine. PLoS One 2013;8(5):e62778
58. Mossler C, Groiss F, Wolzt M, et al. Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1. Vaccine 2013;31(52):6194-200
59. Romanova J, Krenn BM, Wolschek M, et al. Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine. PLoS One 2009;4(6):e5984
60. Wacheck V, Egorov A, Groiss F, et al. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. J Infect Dis 2010;201(3):354-62
61. Wressnigg N, Voss D, Wolff T, et al. Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate. Vaccine 2009;27(21):2851-7
62. Hatta Y, Hatta M, Bilsel P, et al. An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1). 2009 influenza virus. Vaccine 2011;29(12):2308-12
63. Watanabe T, Watanabe S, Kim JH, et al. Novel approach to the development of effective H5N1 influenza A virus vaccines: use of M2 cytoplasmic tail mutants. J Virol 2008;82(5):2486-92 (Pubitemid 351293549)
64. Powell TJ, Silk JD, Sharps J, et al. Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity. J Virol 2012;86(24):13397-406